YouTube video by The Rolling Stones - Topic

PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study  Nasdaq

YouTube video by skrajnieskonczony

YouTube video by Windy Hill Studio Austin

Background/Purpose: Osteoarthritis of the knee (OAK) is a common and severe disease. Current treatments provide temporary pain relief, demonstrating unmet need. PCRX-201 is a high capacity, nonintegra...

The objective of this study is to investigate the safety, biodistribution, and exploratory clinical outcomes of enekinragene inzadenovec (PCRX-201), a high-capacity, nonintegrating, nonreplicating ade...

7 AFL prompts. Rarer answers gain more metres. How far can you kick it?

YouTube video by Chance Meeting

Pacira BioSciences' intra-articular gene therapy showed durable tolerability and exploratory pain improvements over two years in moderate-to-severe knee osteoarthritis.

Click to view the official SEC document.

Click to view the official SEC document.

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee...

Pacira BioSciences (NASDAQ:PCRX) reported publication of positive two-year Phase 1 data for PCRX-201, its investigational locally administered gene therapy for moderate-to-severe knee osteoarthritis, in Annals of the Rheumatic Diseases. A single intra-articular knee injection of PCRX-201 was well tolerated over 104 weeks.The open-label Phase 1 trial enrolled 72 adults aged 30–80 years in two parts across low, middle, and high doses, with Part 2 adding methylprednisolone pretreatment. Exploratory outcome measures showed improvements in pain, stiffness, and function across all dose cohorts among participants who remained in the study. Glucocorticoid pretreatment was associated with a lower rate of joint effusion and greater clinical improvement and has been incorporated into Pacira’s ongoing Phase 2 ASCEND trial, which has initiated Part B enrollment and targets a first topline readout by year-end 2026.

Pacira BioSciences (Nasdaq:PCRX) reported second quarter 2026 total revenue of $192.4 million, up 6% year over year. GAAP net income was $4.7 million, or $0.12 per share, versus a $4.8 million loss a year ago. Non-GAAP net income was $29.5 million and adjusted EBITDA was $48.7 million.EXPAREL net product sales were $147.8 million (+3%), ZILRETTA sales were $32.6 million (+4%), and iovera° sales were $6.8 million (+22%). Pacira closed the divestiture of its iovera° business to Zimmer Biomet, receiving $73.6 million at closing and eligibility for up to $140 million in total consideration.According to Pacira, UnitedHealthcare now provides separate reimbursement for EXPAREL in outpatient settings. The company advanced its PCRX-201 gene therapy program into a scalable commercial manufacturing process and Part B enrollment of the Phase 2 ASCEND study. Pacira ended the quarter with $251.0 million in cash and updated 2026 total revenue guidance to $735–$760 million, adjusting for the iovera° sale, while reiterating EXPAREL sales and margin guidance.

Purchase price of approximately $8.1 millionAcquisition increases PharmaCorp's operating network to 15 pharmacies Previously announced second definitive share purchase agreement has received preliminary college approval and is anticipated to close on or about August 17, 2026Additional non-binding letter of intent executed for a proposed pharmacy acquisition in Western CanadaSaskatoon, Saskatchewan--(Newsfile Corp. - July 31, 2026) - PHARMACORP RX INC. (TSXV: PCRX) ("PharmaCorp" or the...

Pacira BioSciences, Inc.

Reported Monday, Jul 27 - 8:07am EDT (TheFly subscription required to read more.)

YouTube video by Frontier Man

Read more